FI972202L - Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun - Google Patents

Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun Download PDF

Info

Publication number
FI972202L
FI972202L FI972202A FI972202A FI972202L FI 972202 L FI972202 L FI 972202L FI 972202 A FI972202 A FI 972202A FI 972202 A FI972202 A FI 972202A FI 972202 L FI972202 L FI 972202L
Authority
FI
Finland
Prior art keywords
androstanes
pregnanes
allosteric modulation
gaba receptors
gaba
Prior art date
Application number
FI972202A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI972202A0 (fi
FI972202A7 (fi
Inventor
Nancy C Lan
Kelvin W Gee
Michael B Bolger
Hasan Tahir
Robert Purdy
Ravindra B Upasani
Original Assignee
Cocensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocensys Inc filed Critical Cocensys Inc
Publication of FI972202A0 publication Critical patent/FI972202A0/fi
Publication of FI972202A7 publication Critical patent/FI972202A7/fi
Publication of FI972202L publication Critical patent/FI972202L/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI972202A 1994-11-23 1995-11-22 Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun FI972202L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34692694A 1994-11-23 1994-11-23
PCT/US1995/015210 WO1996016076A1 (en) 1994-11-23 1995-11-22 Androstane and pregnane series for allosteric modulation of gaba receptor

Publications (3)

Publication Number Publication Date
FI972202A0 FI972202A0 (fi) 1997-05-23
FI972202A7 FI972202A7 (fi) 1997-07-17
FI972202L true FI972202L (fi) 1997-07-17

Family

ID=23361616

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972202A FI972202L (fi) 1994-11-23 1995-11-22 Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun

Country Status (27)

Country Link
EP (1) EP0808325B1 (cs)
JP (1) JPH10509458A (cs)
KR (1) KR100394548B1 (cs)
CN (1) CN1171114A (cs)
AP (1) AP653A (cs)
AT (1) ATE198753T1 (cs)
AU (1) AU707486B2 (cs)
BR (1) BR9509764A (cs)
CA (1) CA2205919A1 (cs)
CZ (1) CZ292881B6 (cs)
DE (1) DE69519945T2 (cs)
DK (1) DK0808325T3 (cs)
ES (1) ES2155543T3 (cs)
FI (1) FI972202L (cs)
GE (1) GEP20002033B (cs)
GR (1) GR3035562T3 (cs)
HU (1) HUT77087A (cs)
IL (1) IL116108A (cs)
IS (1) IS4488A (cs)
MX (1) MX9703826A (cs)
NO (1) NO308950B1 (cs)
NZ (1) NZ298567A (cs)
PL (1) PL182898B1 (cs)
PT (1) PT808325E (cs)
RU (1) RU2176248C2 (cs)
UA (1) UA48154C2 (cs)
WO (1) WO1996016076A1 (cs)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US6780853B1 (en) 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
RU2194712C2 (ru) * 1995-06-06 2002-12-20 Коукенсис, Инк. НЕЙРОАКТИВНЫЕ СТЕРОИДЫ, ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ НАРУШЕНИЙ, СПОСОБ ИНДУКЦИИ СНА И СПОСОБ ИНДУКЦИИ АНЕСТЕЗИИ С ИХ ИСПОЛЬЗОВАНИЕМ, СПОСОБ МОДУЛИРОВАНИЯ КОМПЛЕКСА РЕЦЕПТОР ГАМКa-ХЛОРИДНЫЙ ИОНОФОР
US20010051599A1 (en) 1997-05-02 2001-12-13 Michael Z. Kagan Pregnan-3-ol-20-ones
CN1270718C (zh) * 1998-03-11 2006-08-23 托布乔恩·贝克斯托罗姆 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
US8771740B2 (en) 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
MXPA02006079A (es) 1999-12-20 2004-08-23 Nicholas J Kerkhof Proceso para producir particulas de nanometro mediante secado por aspersion de lecho fluido.
AR031473A1 (es) * 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
WO2006012563A2 (en) * 2004-07-23 2006-02-02 The Regents Of The University Of California Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
RU2413516C2 (ru) * 2004-11-18 2011-03-10 Умекрин Аб Гамк-стероидные антагонисты и их применение в лечении нарушений цнс
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
DK2097437T3 (en) * 2006-11-21 2015-06-29 Umecrine Cognition Ab THE USE OF PREGNANCY AND ANDROSTANOSTEROIDS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS DISEASES
CN103819525A (zh) * 2008-05-20 2014-05-28 梅克芳股份公司 甾族化合物
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
CN103880909A (zh) * 2008-05-20 2014-06-25 梅克芳股份公司 甾族化合物
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AU2010282570B2 (en) * 2009-08-13 2014-04-24 Marinus Pharmaceuticals, Inc. Method for making 3alpha-hydroxy, 3beta- methyl-5alpha-pregnan-20-one (ganaxolone)
HUE027298T2 (en) 2010-01-14 2016-10-28 Asarina Pharma Ab Pharmaceutical composition containing developed storage and dissolution properties containing 3-beta-hydroxy-5-alpha-pregnan-20-one
WO2011120044A1 (en) * 2010-03-26 2011-09-29 Duke University Conjugated neuroactive steroid compositions and methods of use
JP2014521662A (ja) * 2011-07-29 2014-08-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア GABAA受容体のモジュレーターとしての新規な17β−ヘテロアリール置換ステロイド
HRP20230747T1 (hr) * 2011-09-08 2024-01-05 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihova uporaba
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CN119192266A (zh) * 2011-10-14 2024-12-27 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
MX2015002252A (es) * 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
DK2925327T3 (da) 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
SMT201800657T1 (it) 2013-03-13 2019-01-11 Sage Therapeutics Inc Steroidi neuroattivi e loro metodi di utilizzo
ES2807264T3 (es) 2013-04-17 2021-02-22 Sage Therapeutics Inc Esteroides neuroactivos 19-nor para métodos de tratamiento
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス, インコーポレイテッド 19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
WO2015010054A2 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2848823T3 (es) 2013-08-23 2021-08-12 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA40498A (fr) 2014-09-02 2021-05-19 Texas A & M Univ Sys Méthode de traitement de l'intoxication par organophosphates
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
ME03809B (me) 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016123056A1 (en) 2015-01-26 2016-08-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP4155314A1 (en) 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PL3319611T3 (pl) 2015-07-06 2021-07-12 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
MX382122B (es) 2015-07-06 2025-03-13 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos.
HK1258616A1 (zh) 2016-03-08 2019-11-15 Sage Therapeutics, Inc. 神经活性类固醇、组合物、及其用途
EP3436022B1 (en) 2016-04-01 2022-03-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
PT3519422T (pt) 2016-09-30 2022-12-05 Sage Therapeutics Inc Oxisteróis substituídos em c7 e métodos como moduladores nmda
DK4105223T3 (da) 2016-10-18 2025-07-07 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
CA3041088C (en) 2016-10-18 2024-05-21 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
KR20200011946A (ko) * 2017-06-01 2020-02-04 수미토모 케미칼 컴퍼니 리미티드 복소환 화합물 및 그것을 함유하는 조성물
MA51568A (fr) * 2018-01-12 2021-04-21 Sage Therapeutics Inc Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
US11542296B2 (en) 2018-04-23 2023-01-03 The Texas A&M University System Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders
CN113166193B (zh) 2018-10-12 2025-08-19 萨奇治疗股份有限公司 用于治疗cns病症的在位置10处被环状基团取代的神经活性类固醇
IL283629B2 (en) * 2018-12-05 2026-03-01 Sage Therapeutics Inc Neuroactive steroids and methods of using them
GB201820887D0 (en) * 2018-12-20 2019-02-06 Nzp Uk Ltd Compounds
CN121652218A (zh) * 2019-01-08 2026-03-13 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
US20230257415A1 (en) * 2019-06-27 2023-08-17 Sage Therapeutics, Inc. Compounds for treating cns disorders
JP7787635B2 (ja) 2019-06-27 2025-12-17 セージ セラピューティクス, エルエルシー Cns障害を治療するための組成物及び方法
MX2022010620A (es) * 2020-02-27 2022-11-30 Brii Biosciences Inc Profarmacos de esteroides neuroactivos.
TW202143976A (zh) * 2020-03-18 2021-12-01 美商賽吉醫療公司 神經活性類固醇及其使用方法
WO2023023650A1 (en) * 2021-08-20 2023-02-23 University Of Mississippi Allopregnanolone analogues for hiv viremia and neurotoxicity protection
WO2023060067A1 (en) 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Amorphous solid dispersion ganaxolone formulation
CN115974950A (zh) * 2022-12-23 2023-04-18 上海彩迩文生化科技有限公司 一种3-烷基化的甾体中间体及其制备和应用
CN117801047B (zh) * 2023-01-19 2024-12-20 北京华睿鼎信科技有限公司 神经甾体衍生物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953429A (en) * 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
EP0603312A4 (en) * 1991-09-13 1995-06-07 Cocensys Inc NEW GABA A RECEPTOR WITH STEROID BINDING POINTS.
US5371077A (en) * 1992-08-03 1994-12-06 William Marsh Rice University Side chain derivatized 15-oxygenated sterols, methods of using them and a process for preparing them
AU698834B2 (en) * 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep

Also Published As

Publication number Publication date
CN1171114A (zh) 1998-01-21
ATE198753T1 (de) 2001-02-15
DE69519945D1 (de) 2001-02-22
BR9509764A (pt) 1998-07-07
IL116108A (en) 2002-08-14
PL320416A1 (en) 1997-09-29
AU707486B2 (en) 1999-07-08
CZ292881B6 (cs) 2003-12-17
WO1996016076A1 (en) 1996-05-30
RU2176248C2 (ru) 2001-11-27
KR100394548B1 (ko) 2004-02-05
IL116108A0 (en) 1996-01-31
CZ155397A3 (cs) 1998-03-18
HUT77087A (hu) 1998-03-02
FI972202A0 (fi) 1997-05-23
EP0808325A1 (en) 1997-11-26
AP9700998A0 (en) 1997-07-31
AP653A (en) 1998-07-21
FI972202A7 (fi) 1997-07-17
CA2205919A1 (en) 1996-05-30
MX9703826A (es) 1998-02-28
UA48154C2 (uk) 2002-08-15
DK0808325T3 (da) 2001-01-29
GR3035562T3 (en) 2001-06-29
DE69519945T2 (de) 2001-06-07
GEP20002033B (en) 2000-04-10
PL182898B1 (pl) 2002-03-29
NO972320L (no) 1997-07-23
NO972320D0 (no) 1997-05-21
IS4488A (is) 1997-05-23
AU4408596A (en) 1996-06-17
PT808325E (pt) 2001-06-29
ES2155543T3 (es) 2001-05-16
NO308950B1 (no) 2000-11-20
NZ298567A (en) 2000-01-28
EP0808325A4 (cs) 1997-12-17
EP0808325B1 (en) 2001-01-17
JPH10509458A (ja) 1998-09-14

Similar Documents

Publication Publication Date Title
FI972202L (fi) Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun
FI963174L (fi) Androstaanit ja pregnaanit GABA-reseptorin allosteeriseksi moduloimiseksi
EP0975708A4 (en) METHODS AND MATERIALS FOR XANTHANIC DEGRADATION
DE69616873D1 (de) Überbrückungsvorrichtung für Gelenkprothese
ATE219329T1 (de) Neue verwendung von n-(phosphonomethyl)-glycin und derivaten davon
FI962932A7 (fi) Ankkuriproteiinifunktion modulaattoreita
HUT76781A (en) Mortar for fixing of fixing parts
DE69840871D1 (de) Gerät für multipräzision ganzzahliger arithmetik
EP0809509A4 (en) ALLOSTERIC REGULATION OF NUCLEAR HORMONE RECEPTORS
FI96317C (fi) Menetelmä hienojakoisten ja muunnettujen tärkkelyksien valmistamiseksi
FI953036A7 (fi) Elastomeeristen aineiden parannuksia ja niiden uudelleenkäyttö
FI940029A7 (fi) Uusi menetelmä imidatsolin rikkijohdannaisten valmistamiseksi ja uusia välituotteita
FI940030L (fi) Uusi menetelmä imidatsolin rikkijohdannaisten valmistamiseksi ja uusiavälituotteita
DE69632127D1 (de) Haftmittel für zahnprothesen
KR970016465U (ko) 부품 조립용 체결장치
NO964817D0 (no) Fremgangsmåte for bygging av en rörledning
HK1005243A (en) Androstane and pregnane series for allosteric modulation of gaba receptor
FI955110L (fi) Menetelmä massan sakeuden lisäämiseksi
KR960002700U (ko) 전자사진 응용기기의 수동급지장치
KR970012723U (ko) 연료 호스의 체결구조
FI2738U1 (fi) Levitin polttoainepatruunaa varten ja polttoainepatruuna
FI971378A7 (fi) Menetelmiä ja välituotteita 3-aminobentso(b)-atsepinonien valmistusta varten
HU9401662D0 (en) Mixture of additines for recalling and fixing of latent draulings esspecially dermatogrine markings
KR970014037U (ko) 배기관의 연결용 고정부재
KR970014046U (ko) 배기관의 연결용 고정부재

Legal Events

Date Code Title Description
MA Patent expired